Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3 - Wikidata - awgldk - TriplyDB

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

http://www.wikidata.org/entity/Q36793441

about

MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy Other targeted drugs in melanoma Melanoma: oncogenic drivers and the immune system Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy Targeting of erbB3 receptor to overcome resistance in cancer treatment Pathways and therapeutic targets in melanoma Targeted therapies in development for non-small cell lung cancer Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas.Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors Evaluating melanoma drug response and therapeutic escape with quantitative proteomics Change or die: targeting adaptive signaling to kinase inhibition in cancer cells.Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target FOXD3 Regulates Pluripotent Stem Cell Potential by Simultaneously Initiating and Repressing Enhancer Activity.Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer NF-κB Regulation of c-FLIP Promotes TNFα-Mediated RAF Inhibitor Resistance in Melanoma Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.Dynamical modeling of uncertain interaction-based genomic networks.Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs).Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape.ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation.MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.

P2860

Q26771192-E0FE9B5C-5C33-470B-ABCA-877FB9B76738 Q26775594-C73C0F00-E74C-45F0-B36A-7F1F5AFB4C53 Q26775598-7321CA19-678A-4DFE-AFFC-E519B36AED8A Q26783032-588836B7-34F6-49CA-9C21-CBB6ACC1C7B2 Q26864668-FF1472EF-04C7-441C-B6D3-1F26BB33DC57 Q26865736-AB6929FE-A6FD-4055-BA0C-229E566DF3C1 Q27022852-0A1E83B7-63E2-4A67-8905-49AF9EF0B67C Q27026323-36836AA6-202A-4C67-90D3-8DF8E423D9E5 Q28548486-8344B83E-F0FC-4B34-9C2D-4FED3FD184A2 Q29542169-BA8D8764-4335-4EEA-B1A1-3A5E56778DF2 Q30277902-89835F23-31A6-4945-A7A6-981B6F408A34 Q33610782-8835B002-28D8-4517-987E-58143498A274 Q33629836-958432D5-3BBB-476F-82F5-5C399EE0E41F Q33762715-20BAD0E6-EDA6-47C4-BEDB-2FD5CB800486 Q33784436-34CD0310-373D-4551-85FF-E4D88B6A877D Q33850665-82D67F95-92E8-4300-A186-619DD7AE2B15 Q34225871-97A85866-E804-4AFE-BA67-05F44B13A01C Q34438536-3A4F3AB6-8EB6-4D76-99D7-A8F6E0ACDF9C Q34508290-1506D26F-2A66-4869-A952-52B207980913 Q34677194-2ACAB11A-75EB-4B63-8562-E936D994223A Q34786402-502F90C6-6731-4DB9-AA35-13E080B5ECA4 Q34990555-4B121DCB-B7E6-4505-8D85-657CA09C6406 Q35164121-CF151F41-2403-462E-A83A-24B3682E04E7 Q35384598-79A6CF0B-2C36-4897-83F6-8EE3ACE6C9AC Q35597799-52F241F3-2752-497C-AB93-F94CF9CC29BD Q35657842-4D15522F-42A1-40E2-B212-1894A2513DA6 Q35738534-09666532-377C-425F-A17F-E22BB76CB3F8 Q35743289-7FCDEC80-22C3-4717-9186-FF611CC346E0 Q35794214-FF61DE16-CE90-4D50-B2DC-96C160914D2E Q35812275-4BD3D7F6-6FCE-4391-866B-368F54A872F7 Q35890128-DA9344C5-9BF4-4193-B648-9A1A12C5002A Q36021891-513AB768-7573-413F-B6F2-3FE6FAAF1005 Q36115818-50C2AFE2-8C2A-44C9-AEC2-B41DBAD58972 Q36231908-6639B980-6B5D-474B-A126-3B7BA3BD80A6 Q36238299-50772C0A-A349-487C-A464-9E8A5603410D Q36289114-7ADE0B46-8379-4E3B-8CB1-7A2740E9848B Q36355962-DE50C98D-1E35-48DD-8BC1-5D554D7641AA Q36373537-162369C3-7A61-407F-B2AB-8702D0A23FFD Q36377576-6AD634F7-311B-4B2B-B06A-E452CFD9D1C3 Q36682132-DAE54076-A1E4-4ADD-99A9-37D235D866CD

P2860

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

http://www.wikidata.org/entity/Q36793441

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

@ast

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

@en

type

label

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

@ast

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

@en

prefLabel

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

@ast

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

@en

P1433

Q36793441-7FCB1714-72A9-4BFF-95EA-054140E2A09A

P1476

Q36793441-E27C3A44-F031-489C-B466-1A9F9F4E6F88

P2093

Q36793441-0B0A2633-853A-4A12-BB96-C31C19F258BD

Q36793441-0BA43FC9-E840-40EF-9267-71064E0D4095

Q36793441-1245A371-F2C3-4AAF-8ECE-E5A99E4B080E

Q36793441-1843159E-7300-4654-90B5-40BD91C1C4AF

Q36793441-1EACD7B8-B97C-4D0F-BF19-8239DB99DFCE

Q36793441-24C537C4-D8C0-446C-8275-9CA650C6C62D

Q36793441-2F3703A9-6366-400D-85E6-1140DE85AE8A

Q36793441-8BB1C415-283C-4735-9C31-EC49CAF18465

Q36793441-920AAC88-5DF3-4C63-8484-4073C772D9B6

Q36793441-A3F952D0-9CF3-4CEA-A55E-5A5A4220D4E7

P2860

Q36793441-02A80BD3-C7A1-42F4-A9DE-FF561EE85C2D

Q36793441-03009714-A654-42D4-A490-4D22F391CE9D

Q36793441-055FA816-1FB1-4048-B7B5-2604AC2E05F5

Q36793441-12FCE25C-E32D-4486-A28B-2741C9CB3CA0

Q36793441-19930BBC-CF07-417E-8762-B6BD57893598

Q36793441-202054F4-02AD-4595-8A03-866128452644

Q36793441-29137D2E-BC69-49F3-93A2-7E79801102AB

Q36793441-2A3E6689-42BA-4B81-A426-E4BFCED671BE

Q36793441-3632AC0A-20D7-4D75-863B-156BED1009DD

Q36793441-36725B76-D5A5-4D08-9908-9B8C471847BE

P304

Q36793441-3EFA3CAF-FA9B-489D-8208-CFA1F1EB7E3B

P31

Q36793441-080CB214-98C4-4283-B3C7-C34F029FC70A

P356

Q36793441-935C3CD0-3731-45A4-B2D8-2C0266A0C018

P407

Q36793441-0EC9390F-93E6-4954-8A98-0E2FFF9B330E

P433

Q36793441-3D2BB761-8E0B-45F8-AB20-E11C9B10ABAB

P478

Q36793441-611DE0D4-72DE-4947-8855-87E6A9F5E17B

P577

Q36793441-5974F0FC-4408-4840-A4F2-C3F4DD195646

P5875

Q36793441-5688D9E4-4F87-4E20-8D24-EA258BF7EC24

P698

Q36793441-FB4B143F-9FE6-4B28-8157-8F7DBC53F9B9

P932

Q36793441-5BB06D5F-5175-45D4-BA91-02FD7FFC9C4E

P356

P1433

Journal of Clinical Investigation

P1476

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

@en

P2093

Adam Ertel

http://www.w3.org/2001/XMLSchema#string

Agnieszka K Witkiewicz

http://www.w3.org/2001/XMLSchema#string

Andrew E Aplin

http://www.w3.org/2001/XMLSchema#string

Curtis H Kugel

http://www.w3.org/2001/XMLSchema#string

Ethan V Abel

http://www.w3.org/2001/XMLSchema#string

Giorgos C Karakousis

http://www.w3.org/2001/XMLSchema#string

Jason B Lee

http://www.w3.org/2001/XMLSchema#string

Kaitlyn Le

http://www.w3.org/2001/XMLSchema#string

Kevin J Basile

http://www.w3.org/2001/XMLSchema#string

Lynn M Schuchter

http://www.w3.org/2001/XMLSchema#string

P2860

Model-based analysis of ChIP-Seq (MACS)

Mechanism of activation and inhibition of the HER4/ErbB4 kinase

Targeting androgen receptor in estrogen receptor-negative breast cancer

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Transcriptional competence and the active marking of tissue-specific enhancers by defined transcription factors in embryonic and induced pluripotent stem cells

MEK1 mutations confer resistance to MEK and B-RAF inhibition.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

P304

2155-2168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI65780

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236094378

http://www.w3.org/2001/XMLSchema#string

P698

23543055

http://www.w3.org/2001/XMLSchema#string

P932

3635724

http://www.w3.org/2001/XMLSchema#string